The 2022 FDA Suboxone Dental Warning — Explained
The FDA confirmed what patients had been reporting for years: Suboxone film causes serious dental damage. But the warning came years too late for millions of patients.
FDA Action Summary
- Date: June 2022
- Agency: U.S. Food and Drug Administration (FDA)
- Action: Required class-wide warning label update for all buprenorphine medicines that dissolve in the mouth
- Drugs affected: Suboxone film, Subutex, Zubsolv, Bunavail, and generic equivalents in sublingual/buccal dissolution form
- Reason: Reports of severe dental problems, including in patients with no prior dental history
- Source: FDA Drug Safety Communication
What the FDA Warning Says
The FDA's June 2022 Drug Safety Communication stated the following key findings:
Confirmed Dental Problems
The FDA stated that it received reports of "dental problems in patients using buprenorphine medicines that are dissolved in the mouth." The problems included:
- Tooth decay and dental caries
- Cavities
- Oral infections
- Loss of teeth
Severity Acknowledged
The FDA described the dental problems as "serious" and noted that some patients required multiple tooth extractions and significant dental treatment. The FDA stated that some patients suffered consequences that were "severe" and "life-altering."
No Prior Dental Problems
Critically, the FDA confirmed that dental problems were reported in patients who had no prior dental health issues. This directly refutes the assumption — common among both patients and healthcare providers — that dental damage in buprenorphine patients was simply a consequence of prior substance use.
Timeline After Starting Medicine
The FDA noted that dental problems were reported whether patients had been using the medicine for a short or long time, though they typically arose after the medicine had been used for some duration of treatment.
What the FDA Told Patients to Do
As part of the 2022 warning, the FDA recommended:
- After the medicine fully dissolves, rinse the mouth with water and swallow
- Wait at least 1 hour after the medicine dissolves before brushing teeth (to allow enamel to reharden)
- Schedule regular dental visits and inform the dentist about Suboxone use
- Discuss dental health with prescribing physician
These recommendations came years after the drug was widely prescribed. Millions of patients used Suboxone film without any of this guidance.
What the FDA Told Prescribers
The FDA's June 2022 communication also required prescribers to:
- Counsel patients about the risk of dental problems at each visit
- Tell patients to rinse their mouth after each dose
- Recommend regular dental check-ups
- Ask patients about dental health at follow-up appointments
Why the Warning Matters for Your Legal Claim
The FDA's 2022 dental warning is significant for Suboxone dental injury lawsuits for several reasons:
1. Official Confirmation of the Link
The FDA's communication officially confirms the causal link between buprenorphine sublingual medicines and dental injuries. Plaintiffs no longer need to prove the connection from scratch — a federal regulatory agency has already affirmed it.
2. The Warning Came Years Too Late
The FDA warning was issued in June 2022. Suboxone film was approved and widely prescribed years earlier. Plaintiffs allege that Indivior and Aquestive Therapeutics had access to adverse event data and clinical trial information suggesting dental risk long before 2022 — and failed to act.
3. Failure to Warn
In pharmaceutical product liability litigation, a central theory is "failure to warn" — that the manufacturer knew or should have known about a risk and failed to adequately warn patients and prescribers. The gap between when the dental risk was knowable and when the FDA warning was required is at the heart of these cases.
4. The Discovery Rule Impact
The FDA's June 2022 warning is a significant event for statute of limitations purposes. Many patients only became aware — or only had a reasonable basis to become aware — that Suboxone caused their dental problems after the FDA issued its warning. This may mean your filing deadline started in mid-2022 or later, not when your dental damage first appeared.
The Gap Between What Manufacturers Knew and When They Acted
Central to the Suboxone dental litigation is the allegation that Indivior and Aquestive Therapeutics knew about the dental risk much earlier than 2022 based on:
- Clinical trial data — pre-approval trials may have shown dental adverse events
- Post-marketing adverse event reports — patients and dentists reported dental problems to Indivior's pharmacovigilance systems
- The known chemistry — the film's pH of ~3.4 and its tooth enamel dissolution properties were knowable from the formulation itself
- Scientific literature — research on acid erosion and buprenorphine products was available in the scientific literature before 2022
The FDA Warning Confirmed the Risk. You Deserve to Know Your Rights.
If you used Suboxone sublingual film before the 2022 FDA warning, you may have a claim. A free case evaluation takes 2 minutes.
Check My Eligibility →